Effect of Linagliptin and Voglibose on metabolic profile in patients with Type 2 Diabetes: a randomized, double-blind, placebo-controlled trial

Parthan, Girish ; Bhansali, Shobhit ; Kurpad, Anura V. ; Walia, Rama ; Bhat, Kishor ; Bhansali, Anil (2018) Effect of Linagliptin and Voglibose on metabolic profile in patients with Type 2 Diabetes: a randomized, double-blind, placebo-controlled trial BMC Pharmacology and Toxicology, 19 (1). ISSN 2050-6511

[img] PDF
857kB

Official URL: http://doi.org/10.1186/s40360-018-0228-z

Related URL: http://dx.doi.org/10.1186/s40360-018-0228-z

Abstract

Dipeptidyl peptidase 4 (DPP4) inhibitors improve glycemic control by promoting GLP1-mediated glucose-dependent insulin secretion and suppression of glucagon. Sitagliptin and vildagliptin have been shown to improve insulin sensitivity in patients with type 2 diabetes mellitus (T2DM). However, these patients had uncontrolled blood glucose at inclusion; therefore, the improvement in insulin sensitivity observed in these studies could be attributed to the drug per se and/or reduction in glucotoxicity. This study examines the effect of linagliptin on insulin sensitivity and β-cell function in patients with well-controlled T2DM.

Item Type:Article
Source:Copyright of this article belongs to Springer Nature
Keywords:T2DM, β-cell function, insulin sensitivity, linagliptin, voglibose
ID Code:126263
Deposited On:13 Oct 2022 05:45
Last Modified:13 Oct 2022 05:45

Repository Staff Only: item control page